ReSPECT Glioblastoma Clinical Trial Data to be Presented at 2020 Society for Neuro-Oncology Annual Meeting
October 01 2020 - 7:00AM
Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), today
announced that its abstract regarding lead investigational drug,
Rhenium NanoLiposomes (RNL™), was accepted to the 2020 Society for
Neuro-Oncology (SNO) Annual Meeting being held virtually on
November 19-21, 2020.
“We are looking forward to updating the medical
community on the latest data from our ReSPECT™ Phase 1 trial,” said
Marc Hedrick, M.D., President and Chief Executive Officer of Plus
Therapeutics. “Until then, we will continue to focus on completing
ReSPECT trial enrollment and the chemistry and manufacturing
controls required to advance RNL to the next step of clinical
development.”
The Company will be providing a detailed interim
safety, tolerability, dosing and efficacy data from its ReSPECT
Phase 1 clinical trial of a novel radiotherapy, RNL, in adults with
recurrent glioblastoma (GBM) after standard surgical, radiation,
and chemotherapy treatment. GBM is a rare, incurable and fatal
disease with a median survival of about nine months following
recurrence despite the current standard of care.
ReSPECT is currently supported by an award from
the National Cancer Institute. The Company plans to complete
enrollment in the Phase 1 trial by the end of 2020 and in parallel
will utilize its recently awarded U.S. Food and Drug Administration
(FDA) Orphan Drug and Fast Track designations to determine the next
steps for the program.
Additional details about the ReSPECT trial are
available at clinicaltrials.gov (NCT01906385).
About Plus Therapeutics,
Inc.
Plus Therapeutics (Nasdaq: PSTV) is a
clinical-stage pharmaceutical company whose radiotherapeutic
portfolio is concentrated on nanoliposome-encapsulated
radionuclides for several cancer targets. Central to the Company’s
drug development is a unique nanotechnology platform designed to
reformulate, deliver and commercialize multiple drugs targeting
rare cancers and other diseases. The platform is designed to
facilitate new delivery approaches and/or formulations of safe and
effective, injectable drugs, potentially enhancing the safety,
efficacy and convenience for patients and healthcare providers.
More information may be found at plustherapeutics.com and
respect-trials.com.
About The Society for
Neuro-Oncology
The Society for Neuro-Oncology exists to advance
multi-disciplinary brain tumor research, education, and
collaboration to drive discovery and improve patient care. Over
2,600 neuro-oncology professionals are anticipated to register for
the 25th Annual Scientific Meeting and Education Day being held
virtually on November 19-21, 2020. More information can be found at
soc-neuro-onc.org.
Cautionary Statement Regarding
Forward-Looking Statements
This press release contains certain statements
that may be deemed “forward-looking statements” within the meaning
of U.S. securities laws. All statements, other than statements of
historical fact, that address activities, events or developments
that we intend, expect, project, believe or anticipate and similar
expressions or future conditional verbs such as will, should,
would, could or may occur in the future are forward-looking
statements. Such statements are based upon certain assumptions and
assessments made by our management in light of their experience and
their perception of historical trends, current conditions, expected
future developments and other factors they believe to be
appropriate. These statements include, without limitation,
statements about: the Company’s potential to facilitate new
delivery approaches and/or formulations of safe and effective,
injectable drugs, potentially enhancing the safety, efficacy and
convenience for patients and healthcare providers; the Company’s
potential to develop drug candidates currently in its product
pipeline; and the Company’s potential to develop additional drugs
outside of its current pipeline. The forward-looking statements
included in this press release are subject to a number of
additional material risks and uncertainties, including but not
limited to: the risk that the Company is not able to successfully
develop product candidates that can leverage the U.S. FDA’s
accelerated regulatory pathways; and the risks described under the
heading “Risk Factors” in the Company’s Securities and Exchange
Commission filings, including in the Company’s annual and quarterly
reports. There may be events in the future that the Company is
unable to predict, or over which it has no control, and its
business, financial condition, results of operations and prospects
may change in the future. The Company assumes no responsibility to
update or revise any forward-looking statements to reflect events,
trends or circumstances after the date they are made unless the
Company has an obligation under U.S. federal securities laws to do
so.
Investor ContactPeter VozzoWestwicke/ICR(443)
377-4767 Peter.Vozzo@westwicke.com
Media ContactTerri ClevengerWestwicke/ICR(203)
856-4326Terri.Clevenger@westwicke.com
Plus Therapeutics (NASDAQ:PSTV)
Historical Stock Chart
From Mar 2024 to Apr 2024
Plus Therapeutics (NASDAQ:PSTV)
Historical Stock Chart
From Apr 2023 to Apr 2024